Clinical trial
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With…
NCT00004217 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00004217 |
|---|---|
| Title | S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Official title | A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, valspodar |
| Enrollment | 55 |
| Start date | Feb 1, 2000 |
| Primary completion | May 1, 2001 |
| Completion | Mar 1, 2006 |
| First posted | Jun 18, 2004 |
| Last update posted | Mar 6, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: